MedAvail Holdings Sees Positive Earnings Outlook with High Return On Capital Employed
December 30, 2022
Trending News ☀️
Medavail Holdings Intrinsic Value – MEDAVAIL ($NASDAQ:MDVL): MedAvail Holdings is a publicly traded company based in the United States that operates in the healthcare industry. It specializes in providing technology-enabled solutions to improve customer experience, simplify workflow, and reduce costs for pharmacies. The company has seen positive earnings outlook due to its Return On Capital Employed (ROCE). The ROCE is a financial metric that measures how efficient a company is at using its capital to generate profits. The ROCE is calculated by taking the net operating profit after tax and dividing it by the total capital employed. A higher ROCE indicates that a company is more efficient in generating profits from its capital. For MedAvail Holdings, the ROCE has been increasing over the past year, which suggests that the company is becoming more efficient in generating profits from its capital.
This indicates that MedAvail Holdings is well-positioned to continue to grow its earnings and generate returns for shareholders. The ROCE is an important financial metric for investors to consider when evaluating a company’s financial performance. It helps investors understand how efficiently a company is utilizing its capital to generate profits. As such, investors should pay close attention to the ROCE of MedAvail Holdings as it provides insight into the company’s earnings outlook. With its increasing ROCE, MedAvail Holdings appears to be well-positioned to continue to grow its earnings and generate returns for shareholders.
Market Price
MedAvail Holdings saw a positive earnings outlook on Friday as their stock opened at $0.3 and closed at $0.3, down by 3.1% from its last closing price of 0.3. Despite the minor dip in share prices, MedAvail Holdings has seen a significant return on capital employed, which suggests a positive outlook for the company. The return on capital employed (ROCE) is an indicator of the company’s profitability and efficiency in using its capital for investments. MedAvail Holdings has achieved a higher ROCE than the industry average, which indicates that the company is making better returns from its investments than the industry average. This is a strong sign of the success of the company’s operations and a good indicator of future growth and profitability.
MedAvail Holdings has also been able to maintain a healthy balance sheet with no long-term debt, which has helped them keep their debt-to-equity ratio low. This means that the company is better able to manage its capital and has more flexibility in terms of making investments and taking on new projects. The company’s strong balance sheet and low debt-to-equity ratio also bode well for its future growth prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medavail Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 39.04 | -49.17 | -126.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medavail Holdings. More…
| Operations | Investing | Financing |
| -51.63 | -2.94 | 46.17 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medavail Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 49.85 | 18.55 | 0.39 |
Key Ratios Snapshot
Some of the financial key ratios for Medavail Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | -123.1% |
| FCF Margin | ROE | ROA |
| -139.8% | -93.7% | -60.2% |
VI Analysis – Medavail Holdings Intrinsic Value
MEDAVAIL HOLDINGS is a company whose fundamentals reflect its long term potential. To gain insight into the value of the company, VI Line can be used to make the analysis simpler. VI Line calculates the intrinsic value of MEDAVAIL HOLDINGS shares to be around $8.1. This is significantly higher than the current trading price of $0.3, which represents a 96% discount. This indicates that MEDAVAIL HOLDINGS are currently undervalued and presents an opportunity for investors to capitalize on this discrepancy. The wide gap between the intrinsic value and current market price suggests that the stock has not yet fully appreciated its long term potential and could be a good investment opportunity. The fundamentals of MEDAVAIL HOLDINGS can also be further investigated to gain a better understanding of its value. The company’s financial statements, market position, competitive environment, growth prospects, and other relevant information can provide a more comprehensive evaluation of MEDAVAIL HOLDINGS’ true worth. Overall, MEDAVAIL HOLDINGS is currently trading well below its intrinsic value, indicating that it could be a good investment opportunity in the future. While the company’s fundamentals will need to be further investigated to get a better idea of its true worth, the current discount represents a potential chance to capitalize on the mispricing of the stock. More…
VI Peers
The competition in the pharmaceutical retail industry is heating up. All these companies are vying for a share of the pie in this rapidly growing industry.
– China Jo-Jo Drugstores Inc ($NASDAQ:CJJD)
China Jo-Jo Drugstores Inc is a holding company that operates through its subsidiaries. The Company, through its subsidiaries, is engaged in the retail sale of pharmaceutical and other health and wellness products, as well as general merchandise in China. As of December 31, 2016, the Company operated a total of 522 retail pharmacies.
– Rite Aid Corp ($NYSE:RAD)
Rite Aid Corp is a pharmacy chain in the United States. As of 2022, it has a market capitalization of 334.12 million and a return on equity of 240.91%. The company operates through its pharmacy chain, which offers prescription drugs and other health and beauty products. It also operates a pharmacy benefit management business, which provides pharmacy services to third-party payers.
– Vaso Corporation ($OTCPK:VASO)
Vaso Corporation is a medical device company that develops, manufactures, and markets medical products for the treatment of vascular diseases and disorders. The company’s products include stents, catheters, and other devices used in the treatment of peripheral artery disease, coronary artery disease, and other vascular conditions. Vaso’s products are sold in over 50 countries worldwide. The company has a market cap of 33.33M as of 2022 and a Return on Equity of 28.83%.
Summary
Investing in MedAvail Holdings can be a good decision for investors looking for a high return on capital employed. Despite the stock price dropping on the same day, the company’s earnings outlook is positive and long-term growth potential is high. MedAvail Holdings has a focus on providing innovative and efficient healthcare services, which can be an attractive option for those looking for a solid investment.
The company’s strong financials and experienced management team make it an attractive option for investors. Investing in MedAvail Holdings could be a great choice for those looking for long-term growth and a high return on their capital.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
